



### TABLE OF CONTENTS

---

- **Description** p.1
- **Impact Factor** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.2
- **Guide for Authors** p.7



ISSN: 0042-6822

### DESCRIPTION

---

*Virology* publishes the results of basic research in all branches of virology. Benefits include:

No page or color charges **Open Archive**: free access after 12 months for all articles Free access to reviews and special issues Highlighted Articles & Virology blog to promote your article online **Open Access** options available for all articles

The journal features articles on virus replication, virus-host biology, viral pathogenesis, immunity to viruses, virus structure, and virus evolution and ecology. We aim to publish papers that provide advances to the understanding of virus biology.

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our support pages: <http://support.elsevier.com>

### IMPACT FACTOR

---

2013: 3.278 © Thomson Reuters Journal Citation Reports 2014

### ABSTRACTING AND INDEXING

---

BIOSIS  
Chemical Abstracts  
Immunology Abstracts  
MEDLINE®  
EMBASE  
Genetics Abstracts  
Research Alert  
Science Citation Index  
Tropical Diseases Bulletin  
Excerpta Medica  
Biological Abstracts  
Current Contents (Life Sciences, Clinical Medicine)  
Virology and AIDS abstracts  
Scopus

## EDITORIAL BOARD

---

### **Editor-in-Chief:**

**M. Emerman**, Div. of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Seattle, WA 98109-1024, Washington, USA  
: HIV replication; Retroviruses; Evolution of virus-host interactions; Paleovirology

### **Editors:**

**R.C. Condit**, Dept. of Mol. Genetics & Microbiology, University of Florida, 1600 S.W. Archer Street, P.O.Box 100266, Gainesville, FL 32610-0266, Florida, USA  
: Poxviruses and other cytoplasmic DNA viruses; DNA virus transcription and gene regulation; DNA Viruses of Insects

**S. Cherry**, Perelman School of Medicine, Dept. of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104-6076, Pennsylvania, USA  
Arboviruses, virus-host interactions, innate immunity, genetic screens

**A.E. Gorbalenya**, Dept. of Medical Microbiology, Ctr. of Infectious Diseases, Leids Universitair Medisch Centrum (LUMC), Albinusdreef 2, 2333 ZA, Leiden, Netherlands  
: Virus Evolution

**D.M. Knipe**, Dept. of Microbiology and Immunobiology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, Massachusetts, USA

: Herpes viruses; Viral chromatin; Virus-cell interactions; Innate immunity and viral evasion

**P.F. Lambert**, School of Medicine and Public Health, McArdle Lab. for Cancer Research, University of Wisconsin at Madison, 1400 University Ave, Madison, 53706, Wisconsin, USA

: Adenoviruses; Polyomaviruses; Parvoviruses; Papillomaviruses; Carcinogenesis by Small DNA Tumor Viruses

**S.A. Lommel**, Dept. of Plant Pathology, North Carolina State University, 2506 Gardner Hall, Raleigh, NC 27695-7616, North Carolina, USA

: DNA and RNA Plant Viruses; Viroids

**M.H. Malim**, Dept. of Infectious Diseases, Borough Wing, Guy's Hospital, London Bridge, King's College London, London, SE1 9RT, England, UK

: HIV; Other Retroviruses

**I.J. Molineux**, Molecular Genetics & Microbiology, University of Texas, 100 W 24th St, Austin, TX 78712-1095, Texas, USA

: Bacteriophages; Fungal, yeast, and algal viruses; Virus structure and Assembly

**M.B.A. Oldstone**, Dept. of Immunology and Microbial Science, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, California, USA

: Viral pathogenesis and immunity; Arenaviruses; Measles virus; Unconventional viruses

**P. Sarnow**, Dept. of Microbiology & Immunology, Stanford University School of Medicine, 299 Campus Dr, Stanford, CA 94305, California, USA

: Positive-stranded RNA viruses

**B. Sherry**, Dept. of Molecular Biomedical Sciences, North Carolina State University, 4700 Hillsborough Street, Raleigh, NC 27606, North Carolina, USA

: dsRNA viruses; Innate immunity and viral evasion

**T.M. Tumpey**, Div. of Influenza, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE, Atlanta, GA 30333, Georgia, USA

: Orthomyxoviruses

**S.P. Whelan**, Dept. of Microbiology & Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, Massachusetts, USA

: Negative-strand RNA viruses

**J.L. Whitton**, Dept. of Immunology and Microbial Science, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, California, USA

: Viral pathogenesis; Immune responses to virus infection; Coxsackieviruses; Arenaviruses

**J.A. Zack**, Dept. of Microbiology, Immunology and Molecular Genetics, UCLA Health System, 615 Charles E. Young Drive South, Los Angeles, CA 90095, California, USA

: HIV pathogenesis; HIV infection; Human retroviruses

### **Editorial Board:**

**C. Aiken**

**A. Alcami**

**W.J. Atwood**

**S. Bachenheimer**

**J.D. Baines**

**U.B.R. Balasuriya**

**L. Banks**

**W.S. Barclay**

**A.D.T. Barrett**  
**C.F. Basler**  
**P. Beard**  
**D. Beasley**  
**J.M. Bergelson**  
**H-U. Bernard**  
**K. Bossart**  
**M. Brahic**  
**W. Britt**  
**D. Brooks**  
**M. Buchmeier**  
**C.B. Buck**  
**E.M. Campbell**  
**R. Cattaneo**  
**W. Chang**  
**C. Cheng-Mayer**  
**N.D. Christensen**  
**G. Christie**  
**P.R. Clapham**  
**R. Clem**  
**D. Coen**  
**J.I. Cohen**  
**P.L. Collins**  
**E. Collisson**  
**F.L. Cosset**  
**R. Courtney**  
**C. Coyne**  
**J.E. Crowe**  
**B.R. Cullen**  
**B. Damania**  
**A.J. Davison**  
**J.C. de la Torre**  
**E-M. de Villiers**  
**R.M. del Angel**  
**Ph. Despres**  
**F. Diaz-Griffero**  
**P. Digard**  
**D. DiMaio**  
**S.-W. Ding**  
**V. Dolja**  
**E. Domingo**  
**R.W. Doms**  
**J. Doorbar**  
**T.W. Dreher**  
**M. Dreux**  
**Chr. Drosten**  
**J. Dubuisson**  
**J.P. Dudley**  
**S. Duffy**  
**R. Dutch**  
**G. Ebel**  
**R. Eisenberg**  
**R.M. Elliot**  
**L. Enjuanes**  
**F. Ennis**  
**D.T. Evans**  
**M. Evans**  
**K. Faaberg**  
**O. Fackler**  
**E. Falck-Pedersen**  
**B. Falk**  
**B.A. Fane**  
**K. Ferbas**  
**A. Fernandez-Sesma**  
**E. Fodor**  
**I.H. Frazer**  
**B. Fredericksen**

**I.V. Frolov  
M. Gale (Jr.)  
T. Gallagher  
D.A. Galloway  
A.V. Gamarnik  
R.L. Garcea  
F. Garcia-Arenal  
A. Garcia-Sastre  
L. Gehrke  
W. Gibson  
O.V. Gjoerup  
F. Goodrum  
P. Gorry  
H. Gottlinger  
C. Grose  
R. Gummuluru  
K. Gustin  
O.A. Haller  
S. Halstead  
J. Hammond  
Th. Hatziioannou  
B. He  
P. Hearing  
M. Heise  
R. Hendrix  
T. Hobman  
B. Hogue  
E. Holmes  
C.M. Horvath  
S. Hughes  
L. Hutt-Fletcher  
M.J. Imperiale  
S.N. Isaacs  
W.T. Jackson  
E. Jan  
S.K. Jang  
R. Javier  
J.A. Jehle  
M. Johnson  
W. Johnson  
C. Jones  
A. Kajon  
C.C. Kao  
J. Karn  
M. Katze  
Y. Kawaoka  
S. Kenney  
K. Khalili  
M.C. Kielian  
K.-H. Kim  
S.G. Kitchen  
A.J. Klingelhutz  
D. Kolakofsky  
K. Konan  
M. Krystal  
R.W. Kuhn  
M. Lagunoff  
L.A. Laimins  
R.A. Lamb  
T. Lane  
M. Law  
B. Lee  
C. W. Lee  
P.G. Leiman  
S.-L. Liu  
R. Lloyd  
V. Lohmann**

**G. Lomonosoff  
S. Lopez  
G.G. Luo  
S. Macdonald  
J. Mackenzie  
S. Makino  
M. Manchester  
L. M. Mansky  
E. Martinez-Salas  
Y. Matsuura  
A. McBride  
J. Mertz  
E. Mocarski  
J.P. Moore  
D.E. Mosier  
R.W. Moyer  
M.I. Muggeridge  
K. Munger  
M.P. Murtaugh  
P. Nagy  
R.S. Nelson  
G.R. Nemerow  
M.L. Nibert  
S.T. Nichol  
U. O'Doherty  
D.A. Ornelles  
F.A. Osorio  
M. Ott  
J.H.J. Ou  
M. Ozbun  
C. Pager  
P. Palukaitis  
J.S.L. Parker  
G. Parks  
C.R. Parrish  
A.L. Passarrelli  
J.T. Patton  
O Peersen  
A. Pekosz  
P. Pellett  
D. Perez  
S. Perlman  
D.J. Pickup  
T. Pierson  
T. Pietschmann  
D. Pintel  
J.M. Pipas  
R.D. Possee  
A. Powers  
P. Prevelige  
G.F. Rall  
G. Randall  
A. L. N. Rao  
V. Rao  
A.R. Rein  
A. Rethwilm  
F Rey  
A. Rice  
S. Rice  
J. Richt  
E. Robertson  
D. Rochon  
R. B. Roden  
J. Roehrig  
G.F. Rohrmann  
A. Roman  
R.P. Roos**

**M.J. Roossinck  
J. Samulski  
R. Sandri-Goldin  
M.J. Sapp  
B.S. Schaffhausen  
J. T. Schiller  
C.S. Schmaljohn  
A. Schneemann  
J. Schoelz  
H.B. Scholthof  
S. Schultz-Cherry  
B.L. Semler  
P.M. Sharp  
P-Y. Shi  
A. Siddiqui  
M.K. Slifka  
J. Smiley  
S.H. Speck  
D.H. Spector  
P. Staeheli  
L. Stamatatos  
T. Stehle  
D. Steinhauer  
J. Stevens  
K. Strebel  
R. Striker  
B. Sugden  
C. Sullivan  
G. Sunter  
G. Sutter  
I. Söderhäll  
P. Tattersall  
J. Taylor  
T. Tellinghuisen  
M. Tommasino  
R.A. Tripp  
J.L. Van Etten  
J. Verchot  
V. von Messling  
A. Wang  
F. Wang  
R. Webby  
J.M. White  
K.A. White  
S. Whitham  
J.K. Whitmire  
M. Worobey  
M. Yi  
D. Yoo  
A. Zajac  
I. Zehbe  
F.M. Zerbini  
X. Zhou**

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

*Virology* publishes the results of original basic research that advances our understanding of virus biology.

We invite articles in all areas of research on viruses at both molecular and organismal level, including virus replication and gene expression, virus structure and assembly, virus-host interactions, viral pathogenesis and immunity, novel viral vectors, molecular aspects of viral ecology, virus evolution, and molecular and immunologic mechanisms of prevention and therapy of viral infections.

### *Types of paper*

*Virology* publishes three forms of manuscripts: (a) regular manuscripts (b) brief communications consisting of short but complete studies; and (c) invited reviews.

Regular manuscripts present the results of original basic research in all areas of virology described above that break new ground and serve as a valuable addition to the literature in the field.

Brief Communications are short self-contained studies of significant and timely findings. Brief communications should have a maximum of 4 presentation items (combination of figures and tables). The organization of a Brief Communication is the same as that of a Regular manuscript. It is expected that the review of a Brief Communication will take into account the nature of its more limited scope. *Manuscripts describing viral sequences without a significant advance in virus biology are not appropriate as Brief Communications*

Invited Reviews describe cutting-edge developments and themes of interest to virologists. The goal of a review is to focus on a sharply defined topic and to make the information accessible to researchers who work in other areas of virology. Reviews should not cover the field in question comprehensively but rather address fundamental concepts, recent findings, and important unresolved issues. We welcome submission of proposals for reviews. *All review submissions should be pre-approved by invitation either by an editor or by sending a pre-submission inquiry to the Editor-in-chief or another editor of Virology with a proposed review outline.*

Papers will be published in *Virology* under one of the following subheadings:

- Virus Replication/Gene Expression
- Virus Structure and Assembly
- Virus-Cell Biology
- Gene Therapy/Viral Vectors
- Emerging Viruses
- Unconventional Agents
- Viral Pathogenesis
- Immunity
- Technological Advances
- Genomes and Evolution

Authors should understand that space limitations make it impossible to publish manuscripts that describe work that does not break new ground conceptually, particularly if the work merely mirrors work done on a closely related virus without adding significant new knowledge, such as partial sequences of related viruses, evolutionary studies based on partial sequences, or descriptions of antigenic relationships and epitopes. Exceptions will be made, however, if these data reveal new insights into the fundamental properties of the virus.

## Contact details for submission

The editors and their areas of responsibility are [given here](#)

**Peer Review Process:** Each editor is responsible for having manuscripts reviewed and for making the final decision concerning the disposition. Each manuscript is reviewed by at least two reviewers. All manuscripts are reviewed as rapidly as possible, and an editorial decision is usually reached within 4 to 5 weeks of the manuscript's submission.

## BEFORE YOU BEGIN

### Additional Information

#### Requirements for deposition of structural data

For papers describing structures of biological macromolecules from electron microscopy experiments, the 3D map should be deposited at either the EMBL-EBI (UK) or RCSB (USA) EMDB deposition site (<http://www.emdatabank.org/>). Once the map has been deposited, any fitted atomic coordinates should be deposited with the Protein Data Bank (PDB) by following the link provided from the EMDB deposition session. The EMDB and PDB IDs should be included in the manuscript. Both the map and the coordinate data will be made public when the associated article is published.

#### Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

#### Policy and ethics

Publication of a research article in *Virology* is taken to imply that the authors are prepared to distribute freely to academic researchers for their own use any materials (e.g., viruses, cells, DNA clones, antibodies) used in the published experiments. Prior to publication, nucleotide sequences and protein sequences must be deposited with GenBank (Web site: <http://www.ncbi.nlm.nih.gov/Genbank/>) and an accession number obtained for publication in the manuscript. X-ray crystallographic coordinates must be deposited with the Protein Data Bank (Web site: <http://www.rcsb.org/pdb/>).

**DUAL USE RESEARCH OF CONCERN. Authors and reviewers must notify the editor-in-chief if a manuscript reports potential dual use research of concern. The editor-in-chief will evaluate potential dual use research of concern papers and, if necessary, will consult additional reviewers.**

#### Conflict of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

#### Submission declaration

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Please note that online publication of a submitted article prior to acceptance (i.e. under revision) is also strictly forbidden without the written consent of the copyright holder.

#### Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by



the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Copyright**

This journal offers authors a choice in publishing their research: Open access and Subscription.

#### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

#### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

### **Retained author rights**

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.

Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY):** lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee in this journal is **\$1,800**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

Authors are required to submit the names and e-mail addresses of **a minimum** of four potential referees who are not current Editors of the journal.

### **Additional information**

#### **Special Subject Repositories**

Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post certain articles such as those funded by the National Institutes of Health under its Public Access policy (see <http://www.elsevier.com/wps/find/authorsview.authors/fundingbodyagreements> for more details on our policy and specific arrangements with various funding bodies, including NIH).

As an author you retain certain rights such as making copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use. See <http://www.elsevier.com/wps/find/authorsview.authors/authorsrights> for an overview of all of these rights, as well as those of your employer or institution.

**Language Polishing.** Authors who require information about language editing and copyediting services pre- and post-submission please visit <http://www.elsevier.com/wps/find/authorshome.authors/languagepolishing> or contact [authorsupport@elsevier.com](mailto:authorsupport@elsevier.com) for more information. Please note Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services or in any advertising. For more information please refer to our Terms & Conditions [http://www.elsevier.com/wps/find/termsconditions.cws\\_home/termsconditions](http://www.elsevier.com/wps/find/termsconditions.cws_home/termsconditions).

## **PREPARATION**

## **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately. Also, please note the following when uploading your PDF: Do not include line numbers in your PDF since these will be added automatically. Do include page numbers on your PDF since these will not be added automatically. Add contact information for the corresponding author on the title page. As with any new submission, YPYW requires continuous line numbering.

### **Streamline Reviews**

If you have a manuscript that has been reviewed and rejected from a high impact journal (Impact Factor over 8 such as Nature, Science, PNAS, Cell Host Microbe, or PLOS Pathogens), you can send us the original reviews, your rebuttal, and a revised manuscript. You should include these extra items as part of your cover letter. We will consider the manuscript based on these reviews. We reserve the option of sending it for an additional assessment, in which case the additional reviewer(s) will also have access to your previous reviews. However, either way it will save you time as you don't need to start the review process all over again with new reviews. This option works best for manuscripts rejected from a high impact journal for perceived reasons of impact, novelty, or significance.

## **References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

## **Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

### **Material and methods**

Materials and methods should provide sufficient information to permit the work to be repeated and should be kept concise by referring to previously published procedures. With increasing studies on pathogenicity of viruses, it is important that the provenance of viruses be stated clearly.

### **Keywords**

Immediately after the abstract, provide a maximum of 10 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abstract must not exceed 150 words

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. For virus nomenclature, you are urged to consult the International Committee for the Taxonomy of Viruses (ICTV): <http://www.ncbi.nlm.nih.gov/>. Commonly used vernacular names may be used after viruses are first correctly identified. Genetic loci should be italicized; protein products of the loci are not italicized.

Please note that the instructions related to Graphical abstract still apply to all new submissions.

## **REVISED SUBMISSIONS**

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### **Article structure**

#### *Subdivision - unnumbered sections*

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

#### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### *Results*

Results should be clear and concise.

#### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

#### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: [Illustration Service](#).

### **Highlights**

Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### *Database linking*

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

For papers describing experimentally determined structures of biological macromolecules, the atomic coordinates and related experimental data (structure factor amplitudes/intensities and/or NMR restraints and chemical shifts) must be deposited in the PDB at a member site of the Worldwide Protein Data Bank ([wwPDB.org](http://wwPDB.org)). The wwPDB validation report for each structure should be provided upon manuscript submission.

For papers describing structures of biological macromolecules from electron microscopy experiments (all averaging methods, including sub-tomogram averaging), the 3D map should be deposited in EM Data Bank (EMDB: [emdatbank.org](http://emdatbank.org)). Any fitted atomic coordinates should be deposited with the Protein Data Bank (PDB). For electron tomographic studies with no averaging, deposition of one or more representative tomograms in EMD is strongly recommended. The EMD and PDB IDs should be included in the manuscript, together with a brief descriptive title for each accession. In cases where PDB models have been fitted into EMD maps, the correspondences between them should be clearly stated. Both the map and the coordinate data must be made public when the associated article is published.

See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

### **Artwork**

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
  - Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
  - Number the illustrations according to their sequence in the text.
  - Use a logical naming convention for your artwork files.
  - Indicate per figure if it is a single, 1.5 or 2-column fitting image.
  - For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
  - Please note that individual figure files larger than 10 MB must be provided in separate source files.
- A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

*Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

*Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**References**

*Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

*Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

*References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

*Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

*Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

*Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

**Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body

text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### **Open data**

This journal supports Open Data, enabling authors to submit any raw (unprocessed) research data with their article for open access publication on ScienceDirect under the CC BY license. For more information, please visit <http://www.elsevier.com/about/research-data/open-data>.

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

### **AFTER ACCEPTANCE**

### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

### **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>